UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 174 filers reported holding UNIQURE NV in Q1 2023. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19 | -38.7% | 2,930 | +4.8% | 0.00% | – |
| Q2 2023 | $31 | -72.8% | 2,796 | -51.0% | 0.00% | – |
| Q1 2023 | $114 | +90.0% | 5,701 | +110.8% | 0.00% | – |
| Q4 2022 | $60 | -99.9% | 2,705 | -41.3% | 0.00% | – |
| Q3 2022 | $86,000 | -71.1% | 4,612 | -71.3% | 0.00% | – |
| Q2 2022 | $298,000 | +52.8% | 16,043 | +48.0% | 0.00% | – |
| Q1 2022 | $195,000 | +200.0% | 10,843 | +237.9% | 0.00% | – |
| Q4 2021 | $65,000 | -66.0% | 3,209 | -46.6% | 0.00% | – |
| Q3 2021 | $191,000 | +57.9% | 6,007 | +51.7% | 0.00% | – |
| Q2 2021 | $121,000 | +86.2% | 3,960 | +104.3% | 0.00% | – |
| Q1 2021 | $65,000 | +3150.0% | 1,938 | +2292.6% | 0.00% | – |
| Q4 2020 | $2,000 | +100.0% | 81 | +107.7% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 39 | 0.0% | 0.00% | – |
| Q2 2020 | $1,000 | -100.0% | 39 | -100.0% | 0.00% | -100.0% |
| Q2 2018 | $4,334,000 | +114.6% | 114,681 | +33.4% | 0.01% | +166.7% |
| Q1 2018 | $2,020,000 | – | 85,997 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |